CD8A and neoplasm: Additionally, the efficacy of immunotherapies, such as immune checkpoint inhibitors, is largely dependent on the levels of “precursor exhausted” CD8+ T cells, which have been suggested to exist according to studies of multiple tumor models (48–50).